Quick Answer
Altimmune, Inc. reported Cash and Equivalents of $43.76 million for fiscal year 2025.
Altimmune, Inc. Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $43.76M | +18.5% |
| 2024 | $36.93M | -72.7% |
| 2023 | $135.12M | +21.6% |
| 2022 | $111.10M | -41.6% |
| 2021 | $190.30M | +64.2% |
| 2020 | $115.92M | +1193.3% |
| 2019 | $8.96M | -73.4% |
| 2018 | $33.72M | +284.5% |
| 2017 | $8.77M | +204.9% |
| 2016 | $2.88M | -81.5% |
| 2015 | $15.57M | -16.5% |
| 2014 | $18.64M | +77.9% |
| 2013 | $10.48M | -17.5% |
| 2012 | $12.70M | +13.0% |
| 2011 | $11.24M | -4.7% |
| 2010 | $11.79M | +340.8% |
| 2009 | $2.67M | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $61.24M | +94.6% | -66.6% |
| June 30, 2025 | $183.10M | +220.5% | +272.9% |
| March 31, 2025 | $49.10M | -37.8% | +33.0% |
| December 31, 2024 | $36.93M | -72.7% | +17.3% |
| September 30, 2024 | $31.47M | -63.8% | -44.9% |
| June 30, 2024 | $57.13M | -44.2% | -27.7% |
| March 31, 2024 | $78.98M | -24.6% | -41.5% |
| December 31, 2023 | $135.12M | +21.6% | +55.6% |
- Altimmune, Inc. showed an increase of +18.5% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2009–2025 period, Altimmune, Inc.’s cash and equivalents has grown by 1536.8% (from $2.67 million to $43.76 million).
- The most recent figure is from Altimmune, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 6, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: